<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3017">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01704001</url>
  </required_header>
  <id_info>
    <org_study_id>ART-123 IV-2</org_study_id>
    <nct_id>NCT01704001</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment</brief_title>
  <official_title>A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asahi Kasei Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asahi Kasei Pharma Corporation</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the impact of impaired renal function on the pharmacokinetics of ART-123 in
      patients with Disseminated Intravascular Coagulation.

      To investigate the safety of ART-123 in patients with Disseminated Intravascular
      Coagulation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite of Pharmacokinetics</measure>
    <time_frame>pre-dose, 0,2,4,8,24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, Area Under Curve, T1/2,CLtot,CLR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of hemorrhage related adverse events</measure>
    <time_frame>from the start of infusion to 8days after the cessation of infusion</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Disseminated Intravascular Coagulation</condition>
  <arm_group>
    <arm_group_label>Renal impairment grade 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal impairment grade 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal impairment grade 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal impairment grade 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART-123</intervention_name>
    <description>380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days</description>
    <arm_group_label>Renal impairment grade 0</arm_group_label>
    <arm_group_label>Renal impairment grade 1</arm_group_label>
    <arm_group_label>Renal impairment grade 2</arm_group_label>
    <arm_group_label>Renal impairment grade 3</arm_group_label>
    <other_name>Recomodulinâ„¢</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese Association for Acute Medicine-defined DIC criteria score &gt;= 4

          -  Written informed consent from patient or guardian

        Exclusion Criteria:

          -  Patients showing intracranial, pulmonary, gastrointestinal hemorrhage

          -  Patients with a history of cerebrovascular disorders within the past 52 week

          -  Patients with a history of hypersensitivity to the ingredients of ART-123
             preparations

          -  Pregnant women, nursing mothers or possibly pregnant women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Asahi Kasei Pharma Corporation</last_name>
    <phone>81-(0)3-3296-5337</phone>
    <email>ct-info@om.asahi-kasei.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 16, 2012</lastchanged_date>
  <firstreceived_date>October 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ART-123</keyword>
  <keyword>Disseminated Intravascular Coagulation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disseminated Intravascular Coagulation</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
